gdc

Leukemia

Leukemia
Chronic myeloid leukemia (CML) is a blood cancer that results from a genetic abnormality that causes the production of too many white blood cells in the bone marrow. However, CML is not a genetic disease that runs in families.
LeukemiaPatient Stories
Tina Cancio, founder of the LGL Leukemia Foundation, recalls her battle with LGL Leukemia.
Leukemia
An overview of leukemia with information about risk factors, common symptoms, and treatments options, including immunotherapy.
Leukemia
A rundown of the 4 main types of leukemia: acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).
Leukemia
Here are the financial support services available to patients receiving treatment for Leukemia.
LeukemiaLymphomaNewsworthy
The Leukemia & Lymphoma Society (LLS) will be hosting its 8th Annual Rocky Mountain Blood Cancer Conference on Saturday, April 7, 2018, at the Hyatt Regency Aurora-Denver Conference Center. LLS Blood Cancer Conferences are free education events for blood cancer patients, survivors, caregivers, family members and healthcare professionals.
LeukemiaPatient Stories
Shaun Willson’s story is one of daring independence and strength, as he championed through an acute myeloid leukemia diagnosis while also being the primary caregiver to his wife, Deborah, during her battle with metastatic cancer.
LeukemiaNewsworthyWeb Exclusives
This is the first treatment that targets patients with AML and the FLT3-ITD mutation. In this clinical trial, patients who received quizartinib lived longer without disease progression than those receiving chemotherapy.
Cancer BiomarkersLeukemia
In recent years, new treatments for acute myeloid leukemia have improved outcomes. In 2017, 2 new drugs were approved for patients with this type of blood cancer linked to a specific biomarker.
Cancer BiomarkersFDA Approvals, News & UpdatesLeukemiaNewsworthy
This is the first time the FDA has used minimal residual disease (MRD) as a biomarker to approve a specific treatment for patients with acute lymphoblastic leukemia (ALL).
Leukemia
New therapies that are now available for people with this type of cancer have fewer side effects than traditional chemotherapy and can improve survival and quality of life.
CONQUER CamLeukemiaPatient Stories
Joyce Beecher vividly recounts her cancer journey as a caregiver to her husband, Rich Beecher, who was diagnosed with chronic lymphocytic leukemia (CLL) in 2003. Listen to Joyce’s story as she describes their determination to find the best care and treatment for Rich, and encourages patients and caregivers to never give up.
CONQUER CamLeukemiaPatient Stories
Diagnosed in 2003, Rich Beecher has been living with chronic lymphocytic leukemia (CLL) for 15 years. Rich describes his cancer journey – from “Why me?” to focusing on the positive things in his life, including immersing himself more in photography.
Family MembersLeukemia
After his father’s diagnosis of acute lymphoblastic leukemia, 10-year-old Rhett is determined to become an oncologist to help other patients with cancer.
Leukemia
CLL is difficult to diagnose, because the symptoms only manifest in the later stages of the disease. As in all types of care, a late diagnosis often means worse prognosis.
Genetics & CancerLeukemia
Knowing if the patient’s chronic lymphocytic leukemia (CLL) has genetic abnormalities through genetic testing can help doctors select the best treatment.
FDA Approvals, News & UpdatesLeukemiaNewsworthy
In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation.
Leukemia
New findings show that starting with a targeted therapy regimen instead of chemotherapy improves outcomes for patients with chronic lymphocytic leukemia, particularly for those under age 70.
Leukemia
Here are the drugs and financial support services available to patients receiving treatment for Leukemia.
ImmunotherapyLeukemiaLymphomaPersonalized Medicine
Nurse Navigator Claire White describes the way she tells her patients what CAR T-cell therapy is and how it works.
FDA Approvals, News & UpdatesLeukemia
This new chemotherapy-free combination of Imbruvica, a targeted therapy, plus Gazyva, a CD20-directed cytolytic antibody, was recently approved by the FDA as first-line treatment of adults aged 65 or older who are newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Financial SupportLeukemiaPatient Stories
Martin Miralda was fresh out of college when a short visit to the United States helped to save his life after he was diagnosed with leukemia. Despite his lacking health insurance as a non-resident, he received superior medical care through “Charity Care,” a service that covers necessary hospitalization for uninsured people in the country and is available in several states.
Leukemia
Results of a recent study showed that using the targeted therapy Imbruvica (ibrutinib) as the first treatment in older adults with CLL was better than the combination of chemotherapy plus immunotherapy in slowing the progression of the disease.
FDA Approvals, News & UpdatesLeukemia
In May 2019, the FDA approved Tibsovo for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) and an IDH1 mutation, or for patients with AML who are unable to use intensive chemotherapy.
Leukemia
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults. Recently, several new drug combinations without chemotherapy have been approved by the FDA for patients with CLL, providing patients new options when their cancer stops responding to current treatment.
Leukemia
Until recently, the initial treatment for patients with CLL was chemotherapy alone. New targeted therapies are now available for use as the first treatment for CLL. At the 2019 ASCO meeting, 2 experts discussed the benefits of these new treatments.
Leukemia
Chimeric antigen receptor (CAR) T-cell therapy could soon expand into chronic lymphocytic leukemia (CLL). Early clinical trials have shown responses in patients with CLL refractory to other therapies. Predicting which patients will respond is key to advancing CAR T-cell therapy into CLL.
Leukemia
Targeted therapy is at the forefront of chronic lymphocytic leukemia (CLL) treatment. In many cases, targeted agents offer superior outcomes to chemotherapy, with more manageable side effects. Multiple targeted therapy options are available, and some choices depend on certain molecular markers.
Leukemia
Cytogenetic testing is used to identify genomic aberrations in patients with chronic lymphocytic leukemia (CLL). It estimates a patient’s outcomes and can predict response to certain therapies, and therefore is recommended for all patients with CLL at diagnosis.
Leukemia
A new study presented at a major medical meeting showed that fewer patients with treatment-naïve chronic lymphocytic leukemia (CLL) who were treated with acalabrutinib alone or in combination with obinutuzumab had disease progression or died compared with a group of patients treated with the combination of obinutuzumab and chemotherapy.
Leukemia
A 3-drug regimen of acalabrutinib, venetoclax, and obinutuzumab was highly effective in removing all traces of disease from the bone marrow of patients with chronic lymphocytic leukemia, according to study results presented at the American Society of Hematology annual meeting.

Results 1 - 32 of 32

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country